STRIPE partners in precision medicine: laboratory perspective

Ben L Kong¹, Benjamin G Brown², Victoria M Pratt³, Bronwyn Ramey^{4

5}, J Shawn Jones⁶, Sara L Rogers^{2

7

8

9}

Affiliations

¹ Oregon Health & Science University, Knight Cancer Institute, Portland, OR, USA. kongb.rx@gmail.com.
² American Society of Pharmacovigilance, Houston, TX, USA.
³ Indiana University School of Medicine, Indianapolis, IN, USA.
⁴ Phoenix Laboratory Consulting, LLC, Louisville, KY, USA.
⁵ End to End Pharmacogenomics, LLC, Minneapolis, MN, USA.
⁶ Department of Pharmaceutical Sciences, Texas Tech University Health Sciences Center Jerry H. Hodge School of Pharmacy, Dallas, TX, USA.
⁷ Department of Pharmacy Practice, Irma Lerma Rangel School of Pharmacy, Texas A&M University, Kingsville, TX, USA.
⁸ Department of Translational Medical Sciences, School of Medicine, Texas A&M University, Bryan, TX, USA.
⁹ Center for Genomic and Precision Medicine, Institute of Biosciences and Technology, Texas A&M University, Houston, TX, USA.

Review

Ben L Kong et al. Pharmacogenomics J. 2025.

. 2025 Jun 30;25(4):17.

doi: 10.1038/s41397-025-00377-y.

Ben L Kong¹, Benjamin G Brown², Victoria M Pratt³, Bronwyn Ramey^{4

5}, J Shawn Jones⁶, Sara L Rogers^{2

7

8

9}

¹ Oregon Health & Science University, Knight Cancer Institute, Portland, OR, USA. kongb.rx@gmail.com.
² American Society of Pharmacovigilance, Houston, TX, USA.
³ Indiana University School of Medicine, Indianapolis, IN, USA.
⁴ Phoenix Laboratory Consulting, LLC, Louisville, KY, USA.
⁵ End to End Pharmacogenomics, LLC, Minneapolis, MN, USA.
⁶ Department of Pharmaceutical Sciences, Texas Tech University Health Sciences Center Jerry H. Hodge School of Pharmacy, Dallas, TX, USA.
⁷ Department of Pharmacy Practice, Irma Lerma Rangel School of Pharmacy, Texas A&M University, Kingsville, TX, USA.
⁸ Department of Translational Medical Sciences, School of Medicine, Texas A&M University, Bryan, TX, USA.
⁹ Center for Genomic and Precision Medicine, Institute of Biosciences and Technology, Texas A&M University, Houston, TX, USA.

No abstract available

Conflict of interest statement

Competing interests: The authors declare no competing interests.

1. Turner AJ, Nofziger C, Ramey BE, Ly RC, Bousman CA, Agúndez JAG, et al. PharmVar tutorial on CYP2D6 structural variation testing and recommendations on reporting. Clin Pharmacol Ther. 2023;114:1220–37. - PubMed
1. Scott SA. The genetic testing reference materials coordination program: over 10 years of support for pharmacogenomic testing. J Mol Diagn. 2023;25:630–3. - PubMed - PMC
1. Pratt VM, Del Tredici AL, Hachad H, Ji Y, Kalman LV, Scott SA, et al. Recommendations for clinical CYP2C19 genotyping allele selection: a report of the association for molecular pathology. J Mol Diagn. 2018;20:269–76. - PubMed
1. Pratt VM, Cavallari LH, Del Tredici AL, Hachad H, Ji Y, Moyer AM, et al. Recommendations for clinical CYP2C9 genotyping allele selection: a joint recommendation of the association for molecular pathology and college of American pathologists. J Mol Diagn. 2019;21:746–55. - PubMed - PMC
1. Pratt VM, Cavallari LH, Del Tredici AL, Hachad H, Ji Y, Kalman LV, et al. Recommendations for clinical warfarin genotyping allele selection: a report of the association for molecular pathology and the college of American pathologists. J Mol Diagn. 2020;22:847–59. - PubMed - PMC